Jan 3 Juvenescence

The Business Cocktail

Atlas Venture raises USD 250 Million for investing in later-stage

Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the VC shop to bolster its startups through series B and beyond. The early-stage operation has bolstered a couple of startups like Padlock and Unum Therapeutics, to IPOs and trade sales. Atlas Venture Opportunity Fund I (AVOF I) is the VC shop’s remedy for financial requirements. Atlas Venture has USD 250 million to support the portfolio companies as they reach series B and beyond.

Harpoon files USD 86 Million IPO for funding its T-cell engager platform

Harpoon Therapeutics declared for going public with a USD 86.25 million IPO to bolster its portfolio of early-stage T-cell engagers aimed at solid tumors. The South San Francisco-based company filed privately with the SEC which had brought on new investors including OrbiMed, Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures and NS Investment.

Boston Scientific bags Millipede and its device for USD 325 Million

Millipede and Boston Scientific inked the agreement, Boston Scientific gave USD 90 million for a portion of the mitral regurgitation startup’s shares and now the device maker is remunerating USD 325 million to pick up the rest shares of Millipede. Boston Scientific could choose to give USD 325 million and commit to remunerate a USD 125 million commercial milestone to acquire Millipede at any time before it finishes a clinical trial. Alternatively, after completing that trial, Millipede could have forced Boston Scientific to acquire it.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.